Back to top

Analyst Blog

Zacks Equity Research

Gentiva Buys Mississippi Hospice

AMED GTIV

 ZacksTrade Now

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Yesterday, Gentiva Health Services Inc. (GTIV - Analyst Report) announced the acquisition of North Mississippi Hospice for an undisclosed price. While the financial terms of the deal were not divulged, Gentiva revealed that it will finance the purchase from its cash reserves.

The transaction is unlikely to materially affect Gentiva’s earnings in the future. However, it will significantly expand the company’s presence in the Northern Mississippi market as North Mississippi Hospice has branches in Tupelo, Oxford and Southaven in Mississippi. The hospice provider, which was founded in 2006, is based in Oxford, Mississippi.

Gentiva has been using its cash reserves to support its inorganic growth strategy and has been on an acquisition spree in the recent times. North Mississippi Hospice is the third acquisition announced in this quarter.

Earlier this month, Gentiva announced that it has purchased the home health and hospice operations of Washington-based Family Home Care Corporation. Previously, in July 2012, the company announced the acquisition of Indiana-based Advocate Hospice, a leading provider of end of life care.

These acquisitions are aimed at expanding Gentiva’s operating scale as well as its geographic coverage. While the purchase of Family Home Care will expand the company’s foothold in the eastern Washington and northern Idaho markets, the acquisition of Advocate Hospice will expand its coverage in central and southern Indiana and leverage its existing hospice and home health facilities in the state. However, similar to the case of North Mississippi Hospice, these acquisitions are not expected to have a material impact on Gentiva’s earnings.

Gentiva, which competes with Amedisys Inc. (AMED - Analyst Report), carries a Zacks #2 Rank, translating into a short-term Buy rating. We maintain a long-term ‘Outperform’ recommendation on the stock.

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
BITAUTO HOLD BITA 35.28 +14.66%
ANI PHARMACE ANIP 24.64 +13.97%
E HOUSECHINA EJ 11.01 +9.44%
CANADIAN SOL CSIQ 26.90 +6.87%
KNIGHTSBRIDG VLCCF 12.47 +5.50%